Skip to main content

Remote Job Finders (RJF)

Trump’s MFN Pricing Expected To Delay More European Drug Launches

Following Insmed’s decision to hold off on launching a newly approved lung disease drug in Europe, experts anticipate more companies will do the same as they seek to avoid price erosion in the U.S. Will Chinese biotechs fill the void?

Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy

In addition to delivering two approved medicines to Biogen’s portfolio, the acquisition of Apellis Pharmaceuticals will support the future launch of the pharma’s own kidney disease asset, currently in multiple Phase 3 trials.

Takeda Restructuring Could Push More Than 600 US Staffers Out of Jobs

Takeda’s layoffs include cutting 247 people in Massachusetts. The workforce reduction is meant to help offset investments in areas including a product launch for oral drug candidate zasocitinib, for which the pharma today announced positive Phase 3 data.
Scroll to top